[{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WNT974","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for WNT974
Details :
WNT974 is an oral inhibitor of Porcupine, an acyltransferase that plays a key role in Wnt ligand secretion and activity. Wnt signaling pathways are a group of signal transduction pathways, which begin with proteins that pass signals into a cell through c...
Reset All
